Aficamten improved peak oxygen uptake by a mean of 1.1 mL/kg/min at 24 weeks, while metoprolol declined by 1.2 mL/kg/min, yielding a least-squares mean difference of 2.3 mL/kg/min (p<0.0001) in the Phase 3 MAPLE-HCM trial of 175 patients with symptomatic obstructive HCM. Superiority extended to five of six secondary endpoints: 51% of aficamten-treated patients improved by at least one NYHA class versus 26% on metoprolol (p<0.001); Kansas City Cardiomyopathy Questionnaire Clinical Summary Score improved by 6.9 points (p<0.01); resting and Valsalva LVOT gradients were reduced by 30 and 35 mmHg, respectively (both p<0.0001); NT-proBNP fell by 81% (p<0.0001); and left atrial volume index improved (p<0.0001), while left ventricular mass index was not different (p=0.16). Safety profiles were broadly similar (treatment-emergent AEs 73.9% vs 75.9%); aficamten required dose down-titration in 4.5% versus 29.9% for metoprolol, with a modest LVEF reduction (LSM difference -4%) and 1.1% experiencing core-lab LVEF <50%. One death occurred on aficamten in a patient with multiple comorbidities; three metoprolol patients discontinued due to AEs. The core development is a head-to-head, double-blind, active-comparator trial read out at ESC with simultaneous publication, testing aficamten monotherapy against the entrenched first-line beta-blocker standard. MAPLE-HCM was designed to include a less severe oHCM cohort than the pivotal SEQUOIA-HCM, excluding resting obstruction and enrolling patients with higher baseline pVO2, aligning with an upstream treatment intent. The program is currently under regulatory review in the U.S., with a PDUFA date of December 26, 2025, alongside parallel assessments in Europe and China. Strategically, the data attempt to reset first-line therapy. Instead of positioning cardiac myosin inhibition as a rescue for refractory patients or as an add-on to beta-blockers, the sponsor is directly challenging initial pharmacologic management. Demonstrating functional capacity gains while the comparator declines, and showing consistent effects across prespecified subgroups, including newly diagnosed or treatment-naïve patients, targets the clinical inertia that has favored beta-blockers for decades. It also advances the class narrative beyond gradient reduction to improvements in symptom, quality of life, and biomarkers across a broader phenotype, a prerequisite for payer adoption and guideline revision. Against a backdrop where another myosin inhibitor is already commercially available, this readout underscores a race for first-line positioning and differentiation in terms of safety management, titration practicality, and monitoring burden. Operationally, if these results shape practice, sites may see a shift away from the routine initiation of beta-blockers toward earlier myosin inhibition, which raises the requirements for echo-based titration protocols, CPET capacity, and NT-proBNP monitoring. CROs and core labs should expect more active-comparator cardiovascular trials anchored to functional endpoints and standardized CPET, with tighter central echo oversight to manage LVEF risk. For sponsors, the consistency across less severe disease could expand eligible trial pools, but also heightens scrutiny on long-term remodeling signals, given the neutral LVMI finding at 24 weeks. Regulators gain additional support for pVO2 and patient-reported outcomes as decision-relevant measures in oHCM, though labeling will hinge on the totality of evidence from the pivotal program. The following hinge points are regulatory: label scope, any REMS-like monitoring requirements, and whether approval language enables first-line use versus step therapy after beta-blocker failure. Guideline committees will weigh the breadth of benefit, durability, and the operational implications of echo-guided dosing. Ex-U.S. assessments will test how much weight payers and HTA bodies place on pVO2 and quality-of-life gains relative to structural remodeling. Clinically, watch for durability beyond 24 weeks, real-world LVEF management, and the hypertension signal, and readouts from non-obstructive and pediatric studies that could further expand the addressable population. Competitive dynamics could push demand for direct comparisons within the myosin inhibitor class; absent that, adoption may hinge on perceived safety headroom and the feasibility of site-level implementation.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
